Renaissance Technologies LLC bought a new position in shares of Arcellx, Inc. (NASDAQ:ACLX - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 49,100 shares of the company's stock, valued at approximately $3,765,000. Renaissance Technologies LLC owned about 0.09% of Arcellx at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the stock. Invesco Ltd. lifted its holdings in Arcellx by 15.7% during the 4th quarter. Invesco Ltd. now owns 26,550 shares of the company's stock valued at $2,036,000 after buying an additional 3,610 shares in the last quarter. FMR LLC boosted its position in Arcellx by 22.8% in the 4th quarter. FMR LLC now owns 7,956,633 shares of the company's stock valued at $610,194,000 after buying an additional 1,477,360 shares during the period. Federated Hermes Inc. boosted its position in Arcellx by 141.4% in the 4th quarter. Federated Hermes Inc. now owns 156,094 shares of the company's stock valued at $11,971,000 after buying an additional 91,430 shares during the period. Rhenman & Partners Asset Management AB boosted its position in Arcellx by 35.9% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,500 shares of the company's stock valued at $3,336,000 after buying an additional 11,500 shares during the period. Finally, Wells Fargo & Company MN boosted its position in Arcellx by 35.7% in the 4th quarter. Wells Fargo & Company MN now owns 26,638 shares of the company's stock valued at $2,043,000 after buying an additional 7,002 shares during the period. 96.03% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling at Arcellx
In other news, Director Kavita Patel sold 1,500 shares of the business's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $64.57, for a total value of $96,855.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Rami Elghandour sold 38,300 shares of the business's stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $62.02, for a total transaction of $2,375,366.00. Following the completion of the sale, the insider now owns 149,186 shares of the company's stock, valued at approximately $9,252,515.72. This represents a 20.43 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 54,455 shares of company stock valued at $3,408,458 in the last three months. Company insiders own 6.24% of the company's stock.
Arcellx Stock Performance
Arcellx stock traded up $0.84 during trading hours on Monday, hitting $64.55. The company had a trading volume of 359,987 shares, compared to its average volume of 555,420. The firm has a market cap of $3.55 billion, a P/E ratio of -90.91 and a beta of 0.33. Arcellx, Inc. has a 1 year low of $47.88 and a 1 year high of $107.37. The company has a 50-day moving average price of $64.76 and a two-hundred day moving average price of $74.65.
Arcellx (NASDAQ:ACLX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.24). The company had revenue of $15.27 million during the quarter, compared to analysts' expectations of $27.42 million. Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%. As a group, equities research analysts anticipate that Arcellx, Inc. will post -1.58 EPS for the current year.
Arcellx Profile
(
Free Report)
Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).
See Also
Before you consider Arcellx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcellx wasn't on the list.
While Arcellx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
